[Asia Economy Reporter Minji Lee] Appclone announced on the 15th that it has obtained a patent for an antibody specifically recognizing malignant B cells (blood cancer), or its antigen-binding fragment, including a chimeric antigen receptor containing them.
The company stated, "We plan to develop a treatment that overcomes the problems of existing allogeneic therapeutics using one of our platforms, the zCAR-T platform."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
